Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

56.65 -0.97 (-1.69%)
Streaming Delayed Price Updated: 12:52 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,741,616
Open 57.62
Bid (Size) 56.64 (300)
Ask (Size) 56.65 (200)
Prev. Close 57.62
Today's Range 56.37 - 57.70
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up? 
Via The Motley Fool
News headline image
Rolling Into Spreads: Extend Profit Potential with Lower Risk ↗
Learn how a vertical spread options strategy can help reduce risk, lock in gains, and stay invested in winning trades. 
Via InvestorPlace

Performance

YTD
+6.0%
+6.0%
1 Month
+3.1%
+3.1%
3 Month
-6.6%
-6.6%
6 Month
+4.5%
+4.5%
1 Year
+22.4%
+22.4%

More News

Read More
News headline image
3 Unpopular Stocks with Questionable Fundamentals
Via StockStory
News headline image
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes ↗
Via Chartmill
Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom ↗
Via Chartmill
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
3 Reasons to Buy Bristol Myers Squibb Stock ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Dividend Stocks to Hold for the Long Haul ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗
Via The Motley Fool
Topics Bonds Intellectual Property
News headline image
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗
Via The Motley Fool
News headline image
3 Value Stocks We Think Twice About
Via StockStory
News headline image
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Via The Motley Fool
Topics Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 56.65
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 07/01/26 12:52 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 125.87B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 126B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.